Abstract: The invention relates to dextrorphan-derivatives, pharmaceutical compositions and pharmaceutical dosage forms containing such dextrorphan-derivatives as well as the use of those dextrorphan-derivatives and/or compositions for treating and preventing diseases and conditions in man and mammals.

Abstract: The invention relates to dextrorphan-derivatives, pharmaceutical compositions and pharmaceutical dosage forms containing such dextrorphan-derivatives as well as the use of those dextrorphan-derivatives and/or compositions for treating and preventing diseases and conditions in man and mammals.

Abstract: The invention relates to a morphinan-derivative that targets NMDA receptors on pancreatic islets and has the general formula (I) wherein R1 is selected from —OH, —CO2H, —R0, —OR0, —OC(?O)R0, —OC(?O)OR0 or —OC(?O)NHR0; and R2 is selected from —H, —R0, —C(?O)R0, —C(?O)OR0, —C(?O)NHR0 or —C(?NH)—NH—C(?NH)—NH2; wherein R0 is in each case independently selected from —C1-C6-alkyl, -aryl, -heteroaryl, —C1-C6-alkyl-aryl or —C1-C6-alkyl-heteroaryl, in each case independently unsubstituted or substituted; or its physiologically acceptable salt and/or stereoisomer, including mixtures thereof in all ratios, for use in the treatment of a disease or condition, where the disease or condition is insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, obesity, and/or diabetic nephropathy.

Abstract: The invention relates to a morphinan-derivative that targets NMDA receptors on pancreatic islets and has the general formula (I) wherein R1 is selected from —OH, —CO2H, —R0, —OR0, —OC(?O)R0, —OC(?O)OR0 or —OC(?O)NHR0; and R2 is selected from —H, —R0, —C(?O)R0, —C(?O)OR0, —C(?O)NHR0 or —C(?NH)—NH—C(?NH)—NH2; wherein R0 is in each case independently selected from —C1-C6-alkyl, -aryl, -heteroaryl, —C1-C6-alkyl-aryl or —C1-C6-alkyl-heteroaryl, in each case independently unsubstituted or substituted; or its physiologically acceptable salt and/or stereoisomer, including mixtures thereof in all ratios, for use in the treatment of a disease or condition, where the disease or condition is insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, obesity, and/or diabetic nephropathy.

Abstract: The present invention relates to a method of identifying a compound suitable as a lead compound and/or as a medicament for the treatment and/or prevention of diabetes, the method comprising the steps of (a) contacting a test compound with a cell comprising a protein, wherein said protein (i) comprises or consists of the amino acid sequence of any one of SEQ ID NOs: 1 to 29; (ii) is encoded by a nucleic acid molecule comprising or consisting of the sequence of any one of SEQ ID NOs: 59 to 87; (iii) is a fragment of the protein according to (i) or (ii) and exhibits Eph-Receptor-Tyrosine-Kinase activity; or (iv) has a sequence at least 75% identical with the protein according to (i) or (ii) or with the fragment according to (iii) and exhibits Eph-Receptor-Tyrosine-Kinase activity; and (b) determining whether said test compound, upon contacting in step (a) inhibits the Eph receptor tyrosine kinase activity of said protein wherein said inhibition indicates a compound suitable as a lead compound and/or as a medicam